Feed SLXNW
SL

Silexion Therapeutics Ltd. SLXNW · NASDAQ

$0.01 +62.79% (+$0.00)

Summary

45 / 100 · Bulios Score

What speaks for it

  • It earns 628 USD a year on every 100 USD of invested capital.
  • It holds more cash than debt: $2.23M against $1.41M.
  • The share price is below the Bulios Fair Price.

What to watch

  • It passes only 2 of the 9 points of the Piotroski financial health test.
  • For every 100 USD of shareholders' equity it carries 3,205 USD of debt.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks cheap
Bulios Fair Price
Current price $0.007

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Valuation in detail

Is it growing?

Revenue (USD)

Diluted EPS (USD)

  • Analyst estimate

There is not enough revenue history yet to say how fast it grows.

Growth in detail

Does it make money?

Over the last 12 months it made a loss of $6.86M.

Profitability in detail

Is it financially healthy?

Yes

Over the last 12 months it spent more cash than it brought in. It holds more cash than debt. The debt score is low because of the debt-to-equity ratio (32.0x).

Financial health in detail

Does it pay a dividend?

No

It pays no dividend.

Dividends in detail

What do analysts expect?

No coverage

No analyst covers this stock.

Analysts in detail

What does it earn on?

By product

The company reports no revenue by product.

By region

The company reports no revenue by region.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy